Remove 2019 Remove Compounding Remove Labelling
article thumbnail

Extemporaneous Compounding

RX Note

Introduction In 2018, the Ministry of Health Malaysia published the Good Compounding Practice as a guidance for compounding practices. NOTE: When compounding a preparation using the contents of an ampoule , care should be taken to withdraw the solution using a filter needle to avoid incorporating glass particles into the compound.

article thumbnail

Extemporaneous Preparation with Unknown Stability

RX Note

Today, stability information can be obtained from manufacturer’s labelling information (such as in the package insert), the USP compounding monographs, or peer-reviewed articles and references , such as articles in American Journal of Health-System Pharmacy, the International Journal of Pharmaceutical Compounding.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

The characterization of investigative data resulted in a violation related to promotion of an unapproved compound. Correspondingly, the instances of promotion of an unapproved use has diminished and was last named as a violation in 2019.

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

Introducing an irinotecan tablet formulation, in combination with other effective oral compounds, provides the opportunity for patients to receive an all-oral, metronomic chemotherapy with better efficacy in a more convenient and cost-effective regimen. accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf [Accessed 25.01.22].

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. Dr Hoppin began working with Dr John Babich and Noria Therapeutics in 2018, joining their board of directors in 2019 and supporting the subsequent creation and funding of subsidiary PSMA Therapeutics.

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

Dr. Bernard Bihari is credited with making these discoveries about using naltrexone off-label, at lower doses. LDN can be taken in the form of a compounded tablet, capsule, liquid, or transdermal formulation. It’s also best to work with a compounding pharmacy that can help you titrate your dose correctly.

article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

Therefore, with an inadequate or loss of response to these anti-TNFs, clinicians must prescribe adult therapies off-label to treat younger patients. In addition to Skyrizi’s recent supplementary CD indication, both Tremfya and Skyrizi received US FDA approval in psoriasis in 2017 and in 2019, respectively.